JPWO2020061337A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020061337A5 JPWO2020061337A5 JP2021540778A JP2021540778A JPWO2020061337A5 JP WO2020061337 A5 JPWO2020061337 A5 JP WO2020061337A5 JP 2021540778 A JP2021540778 A JP 2021540778A JP 2021540778 A JP2021540778 A JP 2021540778A JP WO2020061337 A5 JPWO2020061337 A5 JP WO2020061337A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims description 166
- 239000000427 antigen Substances 0.000 claims description 155
- 102000036639 antigens Human genes 0.000 claims description 153
- 108091007433 antigens Proteins 0.000 claims description 153
- 239000012634 fragment Substances 0.000 claims description 149
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 229920001184 polypeptide Polymers 0.000 claims description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 108091035707 Consensus sequence Proteins 0.000 claims description 51
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 20
- 108091008874 T cell receptors Proteins 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 210000000056 organ Anatomy 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 8
- 241000282567 Macaca fascicularis Species 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 5
- 230000004068 intracellular signaling Effects 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 201000003708 skin melanoma Diseases 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 3
- 206010072449 Desmoplastic melanoma Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 3
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 3
- 206010029488 Nodular melanoma Diseases 0.000 claims description 3
- 206010048214 Xanthoma Diseases 0.000 claims description 3
- 206010048215 Xanthomatosis Diseases 0.000 claims description 3
- 206010000583 acral lentiginous melanoma Diseases 0.000 claims description 3
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 3
- 230000001461 cytolytic effect Effects 0.000 claims description 3
- 229940127121 immunoconjugate Drugs 0.000 claims description 3
- 201000003731 mucosal melanoma Diseases 0.000 claims description 3
- 201000000032 nodular malignant melanoma Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 230000009702 cancer cell proliferation Effects 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- -1 radiotherapy Substances 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- 150000001413 amino acids Chemical group 0.000 description 38
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 13
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 13
- 101000799569 Homo sapiens Alpha- and gamma-adaptin-binding protein p34 Proteins 0.000 description 10
- 101000992235 Homo sapiens UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102100034181 Alpha- and gamma-adaptin-binding protein p34 Human genes 0.000 description 7
- 102100031929 UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Human genes 0.000 description 7
- 102100038316 Kinesin light chain 4 Human genes 0.000 description 6
- 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 5
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 5
- 102000009609 Pyrophosphatases Human genes 0.000 description 4
- 108010009413 Pyrophosphatases Proteins 0.000 description 4
- 101100203218 Homo sapiens INPP5D gene Proteins 0.000 description 3
- 101000605508 Homo sapiens Kinesin light chain 4 Proteins 0.000 description 3
- 101100508946 Homo sapiens PPA1 gene Proteins 0.000 description 3
- 102000051524 human AAGAB Human genes 0.000 description 3
- 102000051379 human KLC4 Human genes 0.000 description 3
- 102000053330 human OGT Human genes 0.000 description 3
- 108700014420 Chromobox Protein Homolog 5 Proteins 0.000 description 2
- 102100032919 Chromobox protein homolog 1 Human genes 0.000 description 2
- 101710173115 Chromobox protein homolog 1 Proteins 0.000 description 2
- 102100032902 Chromobox protein homolog 3 Human genes 0.000 description 2
- 101710173111 Chromobox protein homolog 3 Proteins 0.000 description 2
- 102100032918 Chromobox protein homolog 5 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 2
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 2
- 101710163100 Kinesin light chain 4 Proteins 0.000 description 2
- 101100489832 Mus musculus Aagab gene Proteins 0.000 description 2
- 101100203219 Mus musculus Inpp5d gene Proteins 0.000 description 2
- 101100453975 Mus musculus Klc4 gene Proteins 0.000 description 2
- 101100341103 Mus musculus Ppa1 gene Proteins 0.000 description 2
- 101000992236 Mus musculus UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Proteins 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 102000030582 inositol polyphosphate 5-phosphatase Human genes 0.000 description 2
- 108060004006 inositol polyphosphate 5-phosphatase Proteins 0.000 description 2
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 2
- 101100453973 Bos taurus KLC4 gene Proteins 0.000 description 1
- 101100341089 Bos taurus PPA1 gene Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100327111 Homo sapiens CBX1 gene Proteins 0.000 description 1
- 101100327120 Homo sapiens CBX5 gene Proteins 0.000 description 1
- 101000797578 Homo sapiens Chromobox protein homolog 3 Proteins 0.000 description 1
- 101100508952 Macaca fascicularis PPA1 gene Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 101710204288 Melanoma-associated antigen 3 Proteins 0.000 description 1
- 101100214733 Rattus norvegicus Aagab gene Proteins 0.000 description 1
- 101100256868 Rattus norvegicus Inpp5d gene Proteins 0.000 description 1
- 101100453976 Rattus norvegicus Klc4 gene Proteins 0.000 description 1
- 101000992231 Rattus norvegicus UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 102000045908 human CBX3 Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733443P | 2018-09-19 | 2018-09-19 | |
| US201862733444P | 2018-09-19 | 2018-09-19 | |
| US201862733435P | 2018-09-19 | 2018-09-19 | |
| US62/733,444 | 2018-09-19 | ||
| US62/733,435 | 2018-09-19 | ||
| US62/733,443 | 2018-09-19 | ||
| PCT/US2019/051967 WO2020061337A1 (en) | 2018-09-19 | 2019-09-19 | Cancer associated antibody compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502079A JP2022502079A (ja) | 2022-01-11 |
| JPWO2020061337A5 true JPWO2020061337A5 (https=) | 2022-11-01 |
| JP2022502079A5 JP2022502079A5 (https=) | 2022-11-01 |
Family
ID=69888817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540778A Pending JP2022502079A (ja) | 2018-09-19 | 2019-09-19 | がん関連抗体組成物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12285484B2 (https=) |
| EP (1) | EP3853377A4 (https=) |
| JP (1) | JP2022502079A (https=) |
| AU (1) | AU2019342131A1 (https=) |
| CA (1) | CA3113223A1 (https=) |
| WO (1) | WO2020061337A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116348483A (zh) * | 2020-07-31 | 2023-06-27 | 南特生物公司 | 嵌合t细胞受体，核酸及其制造和使用方法 |
| CN116635948A (zh) * | 2020-12-07 | 2023-08-22 | Absci公司 | 用于产生疾病相关蛋白质组合物的系统和方法 |
| CN114106187B (zh) * | 2022-01-05 | 2023-01-24 | 中国海洋大学 | 一种靶向ogt的特异性鲨鱼单域抗体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| MX2007008719A (es) | 2005-01-27 | 2007-09-11 | Novimmune Sa | Anticuerpos anti-interferon gamma y metodos de uso de los mismos. |
| US8759490B2 (en) * | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| WO2008063346A2 (en) * | 2006-10-26 | 2008-05-29 | The Research Foundation Of State University Of New York | IL-14α RNA INHIBITORS AND ANTIBODIES TO IL-14α FOR TREATMENT OF AUTOIMMUNE DISEASES AND LYMPHOMAS |
| US20090304590A1 (en) | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| US7763261B2 (en) | 2007-12-19 | 2010-07-27 | Dcb-Usa Llc | Anti-human cytomegalovirus antibodies |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| PT3277821T (pt) | 2015-03-31 | 2019-10-31 | Novimmune Sa | Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos |
| CA2988912C (en) | 2015-06-10 | 2023-09-12 | National Research Council Of Canada | Carbonic anhydrase ix-specific antibodies and uses thereof |
| EP3332637A1 (en) * | 2016-12-09 | 2018-06-13 | Universitätsklinikum Hamburg-Eppendorf | Vhh-containing heavy chain antibody and production thereof |
-
2019
- 2019-09-19 CA CA3113223A patent/CA3113223A1/en active Pending
- 2019-09-19 JP JP2021540778A patent/JP2022502079A/ja active Pending
- 2019-09-19 AU AU2019342131A patent/AU2019342131A1/en not_active Abandoned
- 2019-09-19 WO PCT/US2019/051967 patent/WO2020061337A1/en not_active Ceased
- 2019-09-19 US US17/277,214 patent/US12285484B2/en active Active
- 2019-09-19 EP EP19861397.8A patent/EP3853377A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102595561B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| CA2892371C (en) | Anti-ceacam1 recombinant antibodies for cancer therapy | |
| JP2022536511A (ja) | 癌の処置のための併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用 | |
| JP7384835B2 (ja) | Ｃｄ３に特異的な抗体及びその使用 | |
| CN114173818A (zh) | 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的新辅助联合疗法中的用途 | |
| WO2018133842A1 (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| KR20220097470A (ko) | 항-dll3 작용제의 투여 요법 | |
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| JP2025504738A (ja) | クローディン１８．２アンタゴニストおよびｐｄ－１／ｐｄ－ｌ１系阻害剤の併用療法 | |
| JP2025512026A (ja) | 抗ｃｄ１９剤の投与計画及びその使用 | |
| JP2024506708A (ja) | 特定の乳癌の治療におけるｈｅｒ２を標的とする抗体薬物複合体の使用 | |
| JP7219207B2 (ja) | 腫瘍関連マクロファージを標的化する抗体及びその使用 | |
| JPWO2020061337A5 (https=) | ||
| CN113544143A (zh) | 用于治疗涉及cxcl1功能的疾病的组合物和方法 | |
| JP2026504943A (ja) | 併用療法のための方法および組成物 | |
| TW202346367A (zh) | 涉及抗ｈｌａ－ｇ抗體及抗ｅｇｆｒ抗體、抗ｐｄ１或抗ｐｄ－ｌ１抗體、及／或抗ｃｄ４７抗體之組合療法 | |
| JP2024515879A (ja) | 抗ｓｉｇｌｅｃ組成物及びその使用 | |
| WO2021043810A1 (en) | Anti-fucosyl-gm1 antibodies | |
| WO2026075950A1 (en) | Dosing regimen for anti-dll3 agent | |
| WO2026035616A1 (en) | Combinations for the treatment of cancer | |
| KR20240158391A (ko) | 항-프로그래밍된 사멸-리간드 1(pd-l1) 항체 분자, 암호화 폴리뉴클레오티드 및 사용 방법 | |
| KR20230061499A (ko) | Pd-1 저해제 투여에 의한 암 통증 치료 방법 |